Boston Scientific Corporation · NYSE:BSX
Boston Scientific — Heart Rhythm Society (HRS) 2018 Investor Update
19 slides from Boston Scientific's conference presentation, May 2018
Slide 1: Rhythm Management: Cardiac Rhythm Management and Electrophysiology
Rhythm Management Cardiac Rhythm Management and Electrophysiology Joe Fitzgerald - Executive Vice President & President, Rhythm & Neuro Ken Stein, M.D. - Senior Vice President and CMO, Rhythm Management and Global Health Policy Mark Bickel – Vice President & Global Controller, Rhythm Management
Slide 2: Safe Harbor for Forward-Looking Statements
Safe Harbor for Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,”
Slide 3: Broad Portfolio of Innovative Products and Solutions to Address Large Markets
Broad Portfolio of Innovative Products and Solutions to Address Large Markets Left Atrial Appendage Closure Mapping & Ablation Patient Management Modular CRM Systems* Clinical Evidence Diagnostics & Monitoring* Cardiac Rhythm Management 3 *Implantable Cardiac Monitor (ICM) and Leadless Pacemaker are
Slide 4: Rhythm Management Strategy
Rhythm Management Strategy Expand CRM Leadership Position Scale EP and Expand EP Portfolio Offering Enter New Segments/Markets Achieve Profitability Targets 4
Slide 5: Rhythm Management: Category Leadership & Key Growth Drivers
Rhythm Management: Category Leadership & Key Growth Drivers ICD/CRT-D Pacemaker Diagnostics Electrophysiology Accolade™ MRI HeartLogic™ RESONATETM HV Ingevity™ pacing lead; HF Dx solution: Family of Devices RHYTHMIA™ HDx full-body MRI (1.5T and a composite alert Next gen platform Mapping & 3T) & wir
Slide 6: High Voltage Portfolio – Resonate Family
High Voltage Portfolio – Resonate Family HeartLogicTM Clinical Investments Robust clinical HeartLogic™ shifts heart pipeline driving SmartCRT™ is Boston Scientific’s approach to failure patient management MANAGE_HF towards clinical personalize CRT therapy from reactive treatment to and economic proa
Slide 7: Driving Global Leadless Expansion with Modular CRM (mCRM)
Driving Global Leadless Expansion with Modular CRM (mCRM™) EMBLEM™ MRI S-ICD and EMPOWER™ MPS S-ICD System Enhancements Modular CRM Systems* EMBLEM MRI S-ICD1 Preloaded delivery catheter with • 40,000 WW Implants1 New S-ICD Electrode extendable inner catheter • 8.75 Years mean with Integrated Sleeve
Slide 8: Support Broad S-ICD Coverage by U.S. Payers
Clinical Evidence and Society Guidelines Support Broad S-ICD Coverage by U.S. Payers 2017 AHA/ACC/HRS Guidelines Provide Class I and Medicare and Commercial Payers Class IIa Recommendations4 • Medicare National Coverage Determination provides coverage consistent with S-ICD labeling for all Medicare
Slide 9: Entering a New ~$750M Adjacency in 2019
LUX-Dx™ Insertable Cardiac Monitor Entering a New ~$750M Adjacency in 2019 Diagnostic-only device platform designed for cardiac monitoring Arrhythmia Management (Syncope and AF) and extensible to other diseases* • Competitive device characteristics and implant experience • Algorithms to detect atria
Slide 10: WATCHMAN LAAC Device Global Leadership
WATCHMAN™ LAAC Device Global Leadership WATCHMAN™ • 50,000 worldwide implants • China poised to become #2 global market • Japan on track for 2019 launch • Target 500 WATCHMAN U.S. centers YE 2018 • NESTed registry presented at ACC 20186 • Acute data on 1,000 patients • ~1.5% Major Adverse Event Rate
Slide 11: Electrophysiology: Platform Emerging to Generate Growth > Market
Electrophysiology: Platform Emerging to Generate Growth > Market Electrophysiology Portfolio Mapping and Navigation APAMA RF Balloon System** Therapeutic Catheters DIRECTSENSE* Diagnostic Catheters Therapeutic Catheters LUMIPOINT** • IntellaNav ST EP Recording • IntellaNav MiFi OI Systems Securus Th
Slide 12: 2018 EP Franchise New Product Introductions
2018 EP Franchise New Product Introductions Next Generation Navigation DIRECTSENSE™ Technology LUMIPOINT™ Software Module Enabled Therapeutic Catheters • INTELLANAV™ MiFi OI catheter • Enhanced confidence in the • First ever suite of tools for • Navigation-enabled, mini- location, stability, and pro
Slide 13: 2019 EP Franchise New Product Introductions
2019 EP Franchise New Product Introductions Securus Esophageal INTELLANAV STABLEPOINT™ Apama Single-Shot RF Balloon Temperature Monitoring • Navigation-enabled force- • Irrigated, single-shot RF balloon • Temperature probe collects sensing catheter on a Total Tip system designed to provide energy ra
Slide 14: Apama RF Balloon Catheter Technology: Expanding our Therapeutic Portfolio
Apama RF Balloon Catheter Technology: Expanding our Therapeutic Portfolio Apama RF Balloon Catheter System strengthens EP Portfolio by expanding treatment options for patients with Atrial Fibrillation into “Single-Shot” PVI Balloon Market Design Goals: • Irrigated, single-shot RF balloon system desi
Slide 15: Securus Medical Acquisition: New Technology for Esophageal Temp Monitoring
Securus Medical Acquisition: New Technology for Esophageal Temp Monitoring Utilizes infrared technology to provide physicians with a more accurate tool for rapid, continuous measurement of esophageal temperatures • Temperature probe collects energy radiating off the esophageal wall and converts it t
Slide 16: HRS and ESC-HF: New Data Highlights
HRS and ESC-HF: New Data Highlights HRS Late Breaking Science Other HRS Highlights Presentation Title Presenter Details Topic Data Presented Procedural data from AF-FICIENT study with APAMA RF balloon demonstrates procedure time reduction compared to cryo or RF point by point 74± 29.5 vs 124.4±39 CA
Slide 17: Demonstrated History of Financial Results
Demonstrated History of Financial Results New Rhythm & Neuro Segment Goals* • Top line potential in Neuromodulation (SCS & DBS) & Electrophysiology expected to accelerate growth. • CRM continues to expand into adjacencies & maximizes high voltage investments & replacement curve. • Continue to expect
Slide 18: References
References 1.) Boston Scientific S-ICDs sold to date from Q1 2018 Product Performance Report (PPR) 2.) Internal analysis of Emblem device longevity on Latitude. 3.) Theuns, D, et al. Evaluation of a Novel Algorithm Designed to Reduce Oversensing in the S-ICD. HRS 2016; AB05-01. 4.) Al-Khatib, SM, St
Slide 19: Q&A
i Scientific Q&A 19
Boston Scientific — Heart Rhythm Society (HRS) 2018 Investor Update on 6ix